atai launches Invyxis, as a new company devoted to the creation of novel psychedelics molecules.
Psychedelics
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
MINDCURE reports its Q2 fiscal 2022 results. The Company recorded a loss of CAD$2.95 million. Its cash position is now CAD$13.4 million.
Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions
Awakn files a patent application in support of a new class of molecules for the treatment of addiction.
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Mindmed receives IND clearance from the FDA for MM-120, paving the way for its Phase IIb clinical trial for generalized anxiety disorder.
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Mydecine announces a partnership with Combat Stress and King's College London to provide psychoactive-assisted therapy for PTSD.
Novamind Announces CAD$5 Million Private Placement with Institutional Investor
Novamind announces a CAD$5 million placement with a single institutional investor. Units are priced at CAD$0.40 with a full warrant at CAD$0.50.
Numinus Wellness Inc. Reports Q1 2022 Results
Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.
Momentum Building For U.S. Psychedelics Legal Reform
Sudden indications of a regulatory thaw in the U.S. toward psychedelic medicine bode well for psychedelic stocks in 2022.
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II
Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II.
Awakn Life Sciences Signs MOU with Maps
Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.
Levitee Labs Announces Non-Brokered Private Placement of up to $3,000,000
Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS' clinical trial for MDMA-assisted psychotherapy.
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
Optimi Health submits a patent application for the extraction process for its natural psilocybin extract.
Study Finds 65% Of Americans With Mental Health Conditions Want Access To Psychedelics
A new study conducted by The Harris Poll and Delic Holdings Corp found that 65% of affected Americans want access to psychedelics for mental health.
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
Mydecine signs an LOI to provide The Newly Institute with psilocybin and MDMA for use in Health Canada SAP-approved psychedelics-based therapy.